NASDAQ$SION
Sionna Therapeutics Inc · Q1 2026 earnings
Q1 2026 earnings ·
Briefing
Sionna Therapeutics reported Q1 2026 with no product revenue, net loss of $26.8M, and diluted loss per share of $0.6.
For the period ended 2026-03-31, Sionna Therapeutics reported no product revenue. Net loss $26.8M. R&D $19.0M for CF programs. Cystic fibrosis biotech; clinical development stage.
- Net loss $26.8M.
- R&D $19.0M for CF programs.
- Rising operating expenses.
Headline financials
Revenue & EPS history
Sionna Therapeutics Inc · Revenue · Quarterly
$0
Forward guidance
Cystic fibrosis biotech; clinical development stage.
Tailwinds
- Strong cash from prior offerings.
- Interest income $2.8M.
Headwinds
- Rising operating expenses.
- Clinical data risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 4 quarterly earnings reports · overlaid with Q1 2026
-0.4%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+15.4%
Avg return
30 days after
40%
2 / 5 earnings
Positive
+13.4%
Q2 2025
Best reaction
-11.3%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -11.3% | -12.4% | -21.8% | |
| Q4 2025 | -7.2% | -1.7% | +13.0% | |
| Q3 2025 | -1.6% | +0.4% | +13.0% | |
| Q2 2025 | +13.4% | +17.8% | +32.8% | |
| Q1 2025 | +4.7% | +9.0% | +40.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro